1.Clinical Support of Laboratory As a Culture room in In-Vitro Fertilization Program
Toshio SHIMIZU ; Jun KANEMOTO ; Kyoichi MIYAGAWA ; Akira TAKEDA ; Sayaka CHIGA ; Hiroko SAKON ; Kiyoshi KATO ; Takaaki HONDO ; Kaoru KIMURA
Journal of the Japanese Association of Rural Medicine 2009;58(1):39-45
Taking charge of in-vitro fertilization and embryo transfer in the laboratory per se amounts to a form of clinical support. To infertile patients, it would be of great benefit if laboratory technicians make direct contact with them and give a full account of the procedure.The apprehensions entertained by them regarding infertility treatment would be removed by hearing what they want to know.In hopes of dispelling the patients' fears and doubts, we have recently started to dialogue with the patients. The face-to-face interview has made us feel confident in what we are doing aside from the lab work and feel a sense of responsibility. Moreover, we have become aware of the need to further devote ourselves to reproductive medicine in order to improve the treatment outcome.One third of the questions frequently asked by patients concerns the quality of embryos and the risk of birth defects, which are issues that challenge us involved in reproductive medicine. To give answers to these and other questions most aptly, it is necessary to share all the up-to-date information, data and knowledge among members of the staff concerned.As the tasks to be grappled with fromnow on, there are problems with unsuccessful cases after repeated IVF trials and an increasing number of patients rangingin age from 45 to 49 years. Where the infertility treatment stops is yet to bedecided in the case of elder women.For providing information and psychological support sought by patients, we keenly felt that there is a necessity to establish a closer collaborative inter-departmental relationship.
Clinical
;
Fertilization
;
Laboratory culture
;
Support
;
therapeutic aspects
2.Influence of body fat in cancer patients on residual content of used fentanyl matrix patches
Takeshi Chiba ; Yusuke Kimura ; Hiroaki Takahashi ; Tomohiko Tairabune ; Yoshiaki Nagasawa ; Kaoru Mori ; Yuji Yonezawa ; Atsuko Sugawara ; Sachiko Kawaguchi ; Hidenobu Kawamura ; Satoshi Nishizuka ; Kenzo Kudo ; Kunihiko Fujiwara ; Kenichiro Ikeda ; Go Wakabayashi ; Katsuo Takahashi
Palliative Care Research 2010;5(2):206-212
Purpose: The objective of this study was to investigate whether body fat rate (BFR) and triceps skinfold thickness (TSF) are associated with estimated fentanyl absorption in patients treated with the fentanyl transdermal matrix patch for moderate to severe cancer pain, by measuring the residual content of fentanyl in used matrix patches. Methods: Adult Japanese inpatients experiencing chronic cancer-related pain and receiving treatment for the first time with a transdermal fentanyl matrix patch (Durotep®MT patch) were included in the present study. During the initial application period, BFR was measured using a body fat scale, and TSF was measured by an experienced nurse with an adipometer. One patch was collected from each patient. The residual fentanyl content in used matrix patch was determined by high-performance liquid chromatography. The transdermal fentanyl delivery efficiency was estimated based on the fentanyl content of the used matrix patches. Results: Fifteen adult patients (5 males and 10 females) were included in this study. Nine patches with a release rate of 12.5μg/h and 6 patches with a release rate of 25μg/h were collected. The application site was the chest or upper arm. BFR and TSF both showed a significant positive correlation with delivery efficiency. Conclusion: In malnourished or low-body fat patients receiving DMP, pain intensity should be more carefully monitored, and fentanyl dose adjustment may be required. Additional parameters, such as nutritional status including body fat change, the degree of dry skin, and plasma fentanyl concentration, also require detailed evaluation. Palliat Care Res 2010; 5(2): 206-212